Celadon Pharmaceuticals Plc

LSE CEL.L

Celadon Pharmaceuticals Plc Price to Sales Ratio (P/S) on January 14, 2025: 140.92

Celadon Pharmaceuticals Plc Price to Sales Ratio (P/S) is 140.92 on January 14, 2025, a -83.47% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Celadon Pharmaceuticals Plc 52-week high Price to Sales Ratio (P/S) is 1,019.75 on April 18, 2024, which is 623.64% above the current Price to Sales Ratio (P/S).
Celadon Pharmaceuticals Plc 52-week low Price to Sales Ratio (P/S) is 108.22 on December 20, 2024, which is -23.20% below the current Price to Sales Ratio (P/S).
Celadon Pharmaceuticals Plc average Price to Sales Ratio (P/S) for the last 52 weeks is 550.67.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

LSE: CEL.L

Celadon Pharmaceuticals Plc

CEO	Mr. James Gareth Short
IPO Date	March 31, 2022
Location	United Kingdom
Headquarters	32-33 Cowcross Street
Employees	27
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years